← Leaderboards
Thu H Le
Duke University
$8,088,871
Attributed
$8,449,451
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $885.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,449,451 · 7
By mechanism
R01$7,267,574 · 5
K08$621,945 · 1
KL2$559,932 · 1
Top collaborators
- Josyf Mychaleckyj3 shared
Most similar at Duke University
Same institution · by research overlap
- Myles S Wolf$18,390,362
- Adrian Hernandez$126,943,012
- Bradley G Hammill$15,995,239
- Karen P Alexander$27,753,285
- Henry S. Friedman$12,588,060
Others in their field
Top investigators on “Blood Pressure”
- David R. Weir · University Of Michigan At Ann Arbor$96,362,652
- Michael A Province · Washington University$60,417,406
- Leonardo Trasande · New York University School Of Medicine$55,277,738
- Rohit Varma · University Of Southern California$55,238,158
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$54,376,013
- Jiang He · Tulane University Of Louisiana$45,164,948
Research focus
Blood PressureHypertensionMouse ModelVariantKidney DiseasesGenesDisease ProgressionChronic Kidney FailureGenetic VariantMolecularGeneticParticipantGenotypeEnd Stage Renal FailureAfrican AmericanLinkCardiovascular DiseasesPredispositionSeveritiesKidneyKnockout MiceAtherosclerosis Risk In CommunitiesCohortPathway Interactions
Grant awards (32)
GSTM1-Transsulfuration metabolic axis in kidney disease: therapeutic target in precision medicine$427,725
R01 · FY2025 · DK · contact PI
GSTM1-Transsulfuration metabolic axis in kidney disease: therapeutic target in precision medicine$200,345
R01 · FY2025 · DK · contact PI
GSTM1-Transsulfuration metabolic axis in kidney disease: therapeutic target in precision medicine$703,200
R01 · FY2024 · DK · contact PI
Institutional Career Development Core$559,932
KL2 · FY2023 · TR · contact PI
Safety, Feasibility and Efficacy of Sulforaphane in Chronic Kidney Disease$290,276
R01 · FY2023 · DK · contact PI
Safety, Feasibility and Efficacy of Sulforaphane in Chronic Kidney Disease$290,212
R01 · FY2022 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$345,708
R01 · FY2021 · DK · contact PI
Safety, Feasibility and Efficacy of Sulforaphane in Chronic Kidney Disease$303,715
R01 · FY2021 · DK · contact PI
GSTM1, APOL1, and their joint contribution to severity of hypertension and chronic kidney disease$235,887
R01 · FY2021 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$345,708
R01 · FY2020 · DK · contact PI
GSTM1, APOL1, and their joint contribution to severity of hypertension and chronic kidney disease$235,887
R01 · FY2020 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$346,500
R01 · FY2019 · DK · contact PI
GSTM1, APOL1, and their joint contribution to severity of hypertension and chronic kidney disease$249,387
R01 · FY2019 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$383,298
R01 · FY2018 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$10,906
R01 · FY2018 · DK · contact PI
Renal Mechanisms of Blood Pressure Regulation and Salt Sensitivity by Collectrin$360,390
R01 · FY2017 · DK · contact PI
Contribution of Gstm1 to the severity of hypertension and chronic kidney disease$237,000
R01 · FY2015 · DK · contact PI
Contribution of Gstm1 to the severity of hypertension and chronic kidney disease$237,000
R01 · FY2014 · DK · contact PI
Contribution of Gstm1 to the severity of hypertension and chronic kidney disease$228,705
R01 · FY2013 · DK · contact PI
Contribution of Gstm1 to the severity of hypertension and chronic kidney disease$235,000
R01 · FY2012 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$303,229
R01 · FY2011 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$306,292
R01 · FY2010 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$165,589
R01 · FY2010 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$307,666
R01 · FY2009 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$340
R01 · FY2009 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$258,157
R01 · FY2008 · DK · contact PI
Genes That Regulate Progression of Kidney Disease and Its Cardiovascular Effects$259,452
R01 · FY2007 · DK · contact PI
GENETIC MODIFIERS IN ANGIOTENSIN RECEPTOR-DEFICIENCY$125,253
K08 · FY2005 · DK
GENETIC MODIFIERS IN ANGIOTENSIN RECEPTOR-DEFICIENCY$125,253
K08 · FY2004 · DK
GENETIC MODIFIERS IN ANGIOTENSIN RECEPTOR-DEFICIENCY$125,253
K08 · FY2003 · DK
GENETIC MODIFIERS IN ANGIOTENSIN RECEPTOR-DEFICIENCY$126,333
K08 · FY2002 · DK
GENETIC MODIFIERS IN ANGIOTENSIN RECEPTOR-DEFICIENCY$119,853
K08 · FY2001 · DK